We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03598608
Title Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | ISR | DEU | CAN | AUS

Facility Status City State Zip Country Details
Banner MD Anderson Cancer Center ( Site 0020) Gilbert Arizona 85234 United States Details
City of Hope ( Site 0001) Duarte California 91010 United States Details
Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007) Los Angeles California 90095 United States Details
Pacific Cancer Care ( Site 0006) Monterey California 93940 United States Details
University of California San Francisco ( Site 0023) San Francisco California 94143 United States Details
Dana Farber Cancer Institute ( Site 0002) Boston Massachusetts 02215 United States Details
Fox Chase Cancer Center ( Site 0019) Philadelphia Pennsylvania 19111 United States Details
Texas Oncology-Austin Midtown ( Site 8002) Austin Texas 78705 United States Details
Concord Repatriation & General Hospital ( Site 0203) Concord New South Wales 2139 Australia Details
Princess Alexandra Hospital ( Site 0204) Woollongabba Queensland 4102 Australia Details
Monash Health ( Site 0201) Clayton Victoria 3168 Australia Details
St Vincent s Hospital (Melbourne) Limited ( Site 0202) Fitzroy Victoria 3065 Australia Details
BC Cancer ( Site 0107) Vancouver British Columbia V5Z 1L3 Canada Details
CancerCare Manitoba ( Site 0101) Winnipeg Manitoba R3E 0V9 Canada Details
Princess Margaret Cancer Centre ( Site 0100) Toronto Ontario M5G 2M9 Canada Details
Jewish General Hospital ( Site 0105) Montreal Quebec H3T 1E2 Canada Details
U. klinikum Koeln AOER ( Site 0326) Koeln Nordrhein-Westfalen 50937 Germany Details
Universitaetsklinikum Leipzig AOeR ( Site 0327) Leipzig Sachsen 4103 Germany Details
Rambam Medical Center ( Site 0382) Haifa 3109601 Israel Details
Hadassah Ein Karem Jerusalem ( Site 0383) Jerusalem 9112001 Israel Details
Chaim Sheba Medical Center. ( Site 0380) Ramat Gan 5262001 Israel Details
Sourasky Medical Center ( Site 0381) Tel Aviv 6423906 Israel Details
A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 0351) Bologna Emilia-Romagna 40138 Italy Details
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0354) Meldola Forli-Cesena 47014 Italy Details
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0352) Rozzano Milano 20089 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field